.png){kind=logo}
Get a free quote now.
.svg){kind=small}
Team
Interested in joining the team? Check out open opportunities here!
Our Team
Sirj Goswami
PhD from the department of Bioengineering and Therapeutic Sciences at UCSF, with a research focus in genomics, pharmacokinetics and pharmacometrics. Sirj was a Discovery Fellow at UCSF with 4+ years of industry experience at Genentech and Pfizer. His passion lies in bringing genomics and advanced analytics to the forefront of healthcare. Read more about his work at sirjgoswami.com.
Ron Keizer
PharmD, PhD with over 30+ publications in clinical pharmacology. Ron is also a software engineer and has developed software for applied modeling & simulation used by >50 pharmaceutical companies and the FDA. After various research positions at leading universities, Ron is now our Chief Scientific Officer.
Ranvir Mangat
Bioengineer with 5+ years of experience as a pharmacometrics researcher at Genentech leading PK/PD analytics for various drug candidates in early and late stage clinical trials. Ranvir's interests lie in applying advanced data analytics and software solutions to improve the effectiveness and management of drug treatments.
Alan Potosnak
Distributed systems architect with 20+ years industry experience, Alan, a former VP at Morgan Stanley, is a startup veteran who has held integral engineering roles across fintech, consumer internet/mobile and digital health and enjoys building technologies that are grounded in improving the lives of others. Alan holds an MSc in software engineering from the University of Southampton where he focused on the development of knowledge-intensive applications.
Jon Faldasz
PharmD, BCPS with residency training at Rady Children’s Hospital (Pediatrics) and UC San Diego (Infectious Disease). Jon brings close to ten years of experience as a Clinical Pharmacy Specialist at UCSF and other adult and children’s hospitals, along with expertise in clinical application of pharmacokinetics and in educating healthcare professionals.
Andro Hsu
As a scientist turned product marketer, Andro brings 12 years of experience at startups in precision medicine, health information technology, and the life sciences. After completing a PhD in molecular biology at UC Berkeley, Andro was at 23andMe, Syapse, and GRAIL, helping transform technological innovation from concept to novel commercial product.
Glenn Roberts
Glenn brings over 30 years of experience in healthcare to InsightRX. Over that time, he has held Healthcare IT sales leadership roles with several organizations including Dictaphone, SoftMed Systems and 3M Health Information Systems. He is passionate about developing trusted client relationships and fostering collaboration with customers to help improve patient outcomes and drive organizational value and efficiencies. As Director of Health System Partnerships at InsightRX, Glenn is committed to working side by side with our existing and prospective customers on their model-informed precision dosing journey.
.png)
John Pilla
PharmD with 5+ years of practice in the acute care inpatient hospital setting. John brings with him experience developing and implementing new medication management initiatives, composing policies governing antibiotic use, and designing educational materials for pharmacy department staff. He is excited about the role that precision-dosing will play in helping both large health institutions and individual patients alike.
.png)
Stephanie Hughes
PharmD with residency training in clinical pharmacy at the Boston Veterans Affairs Healthcare System and fellowship training in infectious diseases/antimicrobial stewardship outcomes research from the Rhode Island Infectious Diseases Research Program. Stephanie has experience as an antimicrobial stewardship pharmacist at a Veterans Affairs medical center as well as in the biotechnology industry as a medical science liaison. Personal interests include pharmacy innovation, antimicrobial treatment optimization, and clinically translatable research.
Marc Meyer
Marc brings over two decades of experience testing software and improving quality at a variety of companies, from start-ups to multi-nationals. He's a strong advocate for agile methodology and improving the experience of software users. He enjoys challenging friends in games of strategy and working with rescue dogs.
Renée Gallison
With BAs in Mathematics and Computer Science from Mills College, Renée has 6+ years of experience building modern web applications, from top to bottom, for numerous startups and companies in industries such as health/wellness, real estate, and marketing. She is passionate about building technology that helps make the world a better place and excited to leverage her skills to improve healthcare and patient dosing.
Vanessa Burns
Vanessa is bringing her multifaceted background in scientific research, entrepreneurship, and product management to InsightRX. Prior to joining, Vanessa received her PhD from Stanford University, where her research focused on the neural mechanisms underlying disease states, particularly depression. She also founded a startup which aimed to help people re-align their circadian rhythms during sleep.
Jasmine Hughes
Jasmine is a data scientist at InsightRX with a focus on pharmacometric modeling and simulation, as well as analysis of treatment progression and performance on patient populations. Jasmine received her PhD from UC Berkeley and UCSF in Bioengineering, where she applied next generation sequencing to understand the progression of brain cancer.
Matt Polland
Matt is joining as an experienced developer with a background in physics and healthcare. Prior to joining InsightRX, Matt was a software engineer and an integral member of the teams at consumer and healthcare companies. He is passionate about leveraging his deep expertise in full-stack development in the growing fields of healthcare and precision medicine.
Tedmund Chua
Tedmund joined InsightRX after an undergraduate career in healthcare research and analytics. He has managed business development at the TMCx accelerator, and is now building new features in our precision medicine and analytics platform. He is fascinated of the role that artificial intelligence will play in shaping the future of healthcare.
Dominic Tong
Dominic is a data scientist at InsightRX, focusing on developing and improving pharmacometric models to better serve all patients. Dominic received his PhD from UC Berkeley and UCSF in Bioengineering, where he studied how to optimize genetic association study design to detect rare genetic variants underlying complex phenotypes like asthma and type 2 diabetes.
Grace Bartoo
Grace received a Ph.D. in Bioengineering and an MS in Electrical Engineering from University of Washington. She has more than 25 years of experience in the medical device industry and has spent over 15 years working directly in medical device start ups and has helped bring companies from initial funding to full operations. Grace has led a team of quality, regulatory and clinical personnel in providing consulting services for a wide variety of projects including: preparation of 510(k), PMA, CE and Canadian applications; Design History File and Device Master Record preparation; preparation and execution of multi-site clinical studies; establishment and improvement of Quality Systems; conduct of formal Quality System audits and leading FDA/NB inspections; development and execution of device verifications and validations, and software tool validation to comply with 21 CFR 11 and process validation requirements.
.png)
Peter Benilov
Peter is a software engineer at InsightRX, focusing on backend, infrastructure and integrations. Prior to coming to InsightRX, Peter was a full stack developer at a medical company in Silicon Valley. He received his MA in Computer Engineering from Trinity College Dublin, Ireland. He is passionate about leveraging artificial intelligence to revolutionize the healthcare industry.
John Peters
Having worked in startups, private equity, and digital media, John brings a generalist skill set that spans operations, strategic analysis, and financial planning. He enjoys building scalable processes and using data to make great strategic decisions. John is inspired by the health outcomes achievable via precision dosing and can't wait to see it at scale.
Scientific Advisory Board
Janel Boyle, PharmD, PhD
Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.
Rada Savic, PhD
Dr. Savic's research uses computational methods to study the dynamic interplay between disease progression, drug and biomarker response across relevant scales (molecule, cell, tissue, organ & whole body) in order to determine causal links underlying variability in (safety and efficacy) clinical outcomes. Her goal is to determine the optimal dosage, timing, and duration of therapeutic regimens and ultimately develop precise, personalized treatments.
Michael N. Neely, MD
Dr. Neely is the the director of the University of Southern California Laboratory of Applied Pharmacokinetics and Bioinformatics, and a Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at the Children's Hospital of Los Angeles (CHLA). Dr. Neely's research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and the use models to optimize therapy for individual patients.
Michael Rybak, MPH, PharmD, PhD
Dr. Rybak is an experienced Professor Of Pharmacy and Medicine with an extensive history of working in higher education with a focus in antimicrobial pharmacokinetics and pharmacodynamics (PK/PD) and the assessment of infectious disease health outcomes.
Our Investors
